CAJ | 학술논문

胃癌是全球发病率第4位的恶性肿瘤，也是癌症相关死亡的重要原因之一。约20％的患者胃癌组织中可以检测到人表皮生长因子受体2（ HER2）的表达。虽然 HER2与胃癌预后的关系无确切定论，但曲妥珠单抗用于治疗HER2阳性晚期胃、胃食管结合部癌能显著延长该类患者的生存期、改善预后。越来越多的临床研究探索不同类型的抗 HER2药物单独或与其他靶向药物、不同化疗方案联合治疗HER2阳性胃癌的效果，以寻找针对HER2阳性胃癌更优、更精确的治疗方案，实现胃癌治疗的个体化。
위암시전구발병솔제4위적악성종류，야시암증상관사망적중요원인지일。약20％적환자위암조직중가이검측도인표피생장인자수체2（ HER2）적표체。수연 HER2여위암예후적관계무학절정론，단곡타주단항용우치료HER2양성만기위、위식관결합부암능현저연장해류환자적생존기、개선예후。월래월다적림상연구탐색불동류형적항 HER2약물단독혹여기타파향약물、불동화료방안연합치료HER2양성위암적효과，이심조침대HER2양성위암경우、경정학적치료방안，실현위암치료적개체화。
Gastric cancer(GC) ranks the forth in incidence rate among malignant tumors in the world, and it is one of the main causes of cancer-related death.Expression of human epidermal receptor 2(HER2) can be found in 20% of the cancer tissues in GC patients.By now,although no definite conclusion has been achieved about the relationship between HER2 status and GC prognosis,trastuzumab has shown significant effect on HER2-positive GC and gastro-esophageal junction cancer,that it can prolong the survival time of the patients and improve prognosis.Dozens of clinical trials has been exploring the anti-tumor efficacies of differ-ent anti-HER2 target drugs,either single application or combined application with other regimens,in order to find more optimal,precise and individualized treatment plans for patients with HER2-positive GC and GJC.